Side-by-side comparison of AI visibility scores, market position, and capabilities
Kellanova acquired by Mars Inc. Aug 2024 for $35.9B ($83.50/share); Pringles, Cheez-It, Pop-Tarts, Eggo integrated into Mars global snacking alongside M&M's/Snickers competing with Frito-Lay and Mondelez.
Kellanova (formerly Kellogg Company's global snacking division) was a Chicago, Illinois-based snacking company — creator of Pringles (the world's second-largest potato chip brand), Pop-Tarts, Cheez-It, Rice Krispies Treats, MorningStar Farms plant-based foods, Eggo waffles, and Nutri-Grain cereal bars — that was created in August 2023 when Kellogg Company split into two independent public companies: Kellanova (global snacking brands, cereal outside North America) and WK Kellogg Co. (North American cereal brands). Kellanova was itself acquired by Mars, Incorporated in August 2024 in a $35.9 billion cash transaction ($83.50 per share) — one of the largest food industry acquisitions in history — ending Kellanova's brief 12-month existence as a standalone public company. Mars acquired Kellanova to expand its snacking portfolio (Mars's existing snacking brands include M&M's, Snickers, Twix, Kind bars, and Nature's Bakery) with Kellanova's salty snacks platform (Pringles, Cheez-It) and convenient breakfast products (Pop-Tarts, Eggo) — creating a combined snacking company with $35+ billion in revenue that competes directly with PepsiCo's Frito-Lay and Mondelez International's snacking portfolio. Prior to the Mars acquisition, Kellanova CEO Steve Cahillane had executed the strategic rationale for the split from WK Kellogg: snacking brands (impulse purchase, premium innovation, global growth) warranted a different capital allocation and growth investment profile than mature North American cereal brands (stable cash flow, distribution efficiency). Kellanova's FY2023 revenues totaled approximately $13 billion, with Pringles generating the highest brand-level profitability through its unique pressurized-air canister distribution system.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.